Table 4 Survival compared to literature on prospective clinical trials and retrospective observational studies.

MIBC or locally advanced disease

RC alone

47.4 months [28.9–65.8]

46 months¹

54 months¹⁹

NAC + RC

35.3 months [5.6–64.9]*

77 months¹

68 months¹⁹

IC + RC

19.5 months [0.0–49.1]

–

18–26 months²⁰

Best Supportive Care

3.8 months [3.2–4.4]

–

5.3 months¹⁷

Metastatic or inoperable disease

First-line chemotherapy (1L)

12.6 months [8.8–16.4]

14.0–15.2 months⁴

16.1 months²⁴

12.7–15.8 months⁵

Recurrent disease after RC

7.5 months [0.0–15.6]

5.2 months²⁵

-

Second-line chemotherapy (2L)

6.6 months [4.7–8.4]

5.9–7.0 months^7,8

9.2 months²⁴

Best Supportive Care (BSC)

2.0 months [0.9–3.2]

4.3–4.6 months^5,7

-